Clinical field study
A dog study to measure NOCITA® (bupivacaine liposome injectable suspension) effectiveness was conducted in 182 client-owned dogs undergoing knee surgery. The study design was a randomized, prospective, blinded, placebo-controlled, multicenter study using 5.3 mg/kg NOCITA by infiltration injection during surgery closure. Post-operative pain assessment was evaluated at 0-24 hours, 24-48 hours and 48-72 hours.
The primary variable for effectiveness was evaluated over the first 24-hour time interval. The percent of treatment success for NOCITA was statistically significantly greater than placebo at the first 24-hour time interval (P = 0.0322). The 24-48 hour and 48-72 hour time intervals were evaluated as secondary variables and support effective use of NOCITA for up to 72 hours of analgesia. They were statistically significantly greater than placebo, with P-values of 0.0402 and 0.0432, respectively.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
NOCITA is now available.
“We began using Nocita on patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results. The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively. Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications. Nocita has quickly become standard protocol for analgesia on our cruciate ligament stabilization procedures.”Veterinary Surgeon
Other therapeutics from Aratana
ENTYCE® (capromorelin oral solution)
provides appetite stimulation.
Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE® provides safe, effective appetite stimulation.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.